Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Boston University Charles River Campus · with National Institute on Aging (NIA) · NCT07659964
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50–90 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- June 1, 2026
- Record last updated
- August 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a nearly threefold higher rate of falls compared to neurotypical older adults. There is an urgent need for fall prevention interventions tailored to the unique deficits of individuals with AD. Converging evidence suggests that interventions aiming to reduce fall risk in AD should target both gait and cognition. Rhythmic music interventions, such as Rhythmic Auditory Stimulation (RAS) can harness global brain activation and auditory-motor entrainment to facilitate high-intensity exercise to alleviate AD-related neurocognitive and gait dysfunction. This study aims to assess the neural correlates of gait dysfunction in people with AD, evaluate if baseline neurocognitive impairment is predictive of the effects of RAS, and evaluate RAS benefits for individuals with AD.
Being studied: Metronome
Conditions: Alzheimer Disease (AD); Mild Cognitive Impairment (MCI)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
General Inclusion (both healthy and AD populations):
- Community-dwelling
- Capable of walking short community distances (approximately 10-15 minutes at a time) without assistance from another person or a device (such as a cane).
- Able to communicate with researchers
- Age 50-90 (inclusive)
Population-specific Inclusion criteria
- Healthy -
- No diagnosis of AD
- AD population-
CERAD score of \<1.5 SD from age + education adjusted norms on delayed recall domain or one or more other cognitive domains (i.e. language, attention).
MoCA score between 20-30 MMSE score between 25-30
Exclusion Criteria
- Presence of significant hearing impairment
- Current orthopedic, neurologic or other medical condition that limits the ability to walk.
The MOCA, MMSE and CERAD tests will be completed in-person after the participant consents into the study. If the participant is determined to be ineligible based on their performance on these tests (compared to inclusion requirements listed above), they will be informed that they are not eligible for this study and the study visit will be cancelled. They will then be withdrawn from the study; their clinical tests and study documentation will be maintained for the purposes of completeness, but will not be used for any study analyses.
Recruiting US locations
Boston University Neuromotor Recovery Laboratory
Boston, MA 02215
Site contact: Louis N Awad, PT, DPT, PhD · 617-500-3645 · gaitlab@bu.edu
Study contacts (from the official record)
- Regina Sloutsky, PT, DPT, PhD · 617-500-3645 · reginas@bu.edu
- Louis N Awad, PT, DPT, PhD · 617-500-3645 · louawad@bu.edu
Similar studies in Massachusetts
All neurology studies in Massachusetts →- RecruitingHealthy volunteersPhase 1
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
General Biophysics LLC
- Location
- Boston, MA
- Eligibility basics
- Ages 55–75
- RecruitingPhase 1/Phase 2Overnight stay mentioned
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Vector Y Therapeutics
- Location
- Boston, MA + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
Massachusetts General Hospital
- Location
- Boston, MA
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersEarly Phase 1
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Massachusetts General Hospital
- Location
- Boston, MA
- Eligibility basics
- Ages 40–99